Literature DB >> 7893272

[The solubility and bioequivalence of silymarin preparations].

H U Schulz1, M Schürer, G Krumbiegel, W Wächter, R Weyhenmeyer, G Seidel.   

Abstract

Seven silymarin products (pharmacies only), two of them with two batches each, were analysed for their ingredients, in particular silibinin (CAS 22888-70-6) and tested in vitro for their liberation of active agents. Founded on the results of these tests three products were checked for bioequivalence. Therefore, a typical phase I 3 fold crossover study was performed showing one product (Legalon) to be qualified by an approx. 2 fold higher silibinin availability compared to the two other preparations.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7893272

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


  13 in total

1.  Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?

Authors:  H H Blume; B S Schug
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability.

Authors:  Xinru Li; Quan Yuan; Yanqing Huang; Yanxia Zhou; Yan Liu
Journal:  AAPS PharmSciTech       Date:  2010-04-20       Impact factor: 3.246

3.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

Review 4.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 5.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.

Authors:  Bill J Gurley; Gary W Barone; D Keith Williams; Julie Carrier; Philip Breen; C Ryan Yates; Peng-fei Song; Martha A Hubbard; Yudong Tong; Sreekhar Cheboyina
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

7.  Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.

Authors:  Jian Wei Deng; Ji-Hong Shon; Ho-Jung Shin; Soo-Jin Park; Chang-Woo Yeo; Hong-Hao Zhou; Im-Sook Song; Jae-Gook Shin
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

8.  Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.

Authors:  Yang Han; Dong Guo; Yao Chen; Yu Chen; Zhi-Rong Tan; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-02-17       Impact factor: 2.953

9.  Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity.

Authors:  Suvadra Das; Partha Roy; Runa Ghosh Auddy; Arup Mukherjee
Journal:  Int J Nanomedicine       Date:  2011-06-22

10.  Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.

Authors:  Kwan Yeol Yang; Du Hyeong Hwang; Abid Mehmood Yousaf; Dong Wuk Kim; Young-Jun Shin; Ok-Nam Bae; Yong-Il Kim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.